Company’s PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential ...

Q1 2025 Management View President & CEO Stacy Lindborg announced the initiation of the first clinical site in Imunon's ...

Imunon Inc (IMNN) progresses with pivotal Phase 3 trials while navigating financial hurdles and seeking strategic ...

IMUNON initiates Phase 3 OVATION 3 study for IMNN-001 in advanced ovarian cancer; Phase 2 data accepted for ASCO presentation. IMUNON, Inc. has initiated the first trial site for its Phase 3 ...

Imunon, Inc. ( NASDAQ: IMNN) Q1 2025 Earnings Conference Call May 12, 2025 11:00 AM ET Peter Vozzo - ICR Healthcare, Investor Relations Stacy Lindborg - President & Chief Executive Officer Douglas ...

Analysts estimate that Imunon will report an earnings per share (EPS) of $-0.36. Investors in Imunon are eagerly awaiting the ...

Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit ...

"IMUNON continues to make significant strides towards our goal of transforming the treatment landscape for women with advanced ovarian cancer. In 2024, our Phase 1/2 OVATION 2 Study delivered ...

The latest analyst rating for Imunon (NASDAQ:IMNN) was provided by D. Boral Capital, and Imunon maintained their buy rating. Analysts arrive at stock ratings after doing extensive research ...

The first trial site is Washington University School of Medicine, and IMUNON is currently initiating additional trial sites and working with investigators to begin enrolling study participants.